Skip to main content

PerkinElmer Acquisition of Caliper Clears Anti-Trust Review

NEW YORK (GenomeWeb News) – PerkinElmer today said that its planned acquisition of Caliper Life Sciences has cleared anti-trust reviews in the US and Germany.

The $600 million deal, which was signed early last month, still requires the approval of Caliper's stockholders, among other remaining conditions. The firms previously said that they expect the transaction to close in the fourth quarter of this year, but they didn't provide an update to that expectation today.

The deal will broaden PerkinElmer's reach in the life sciences research space, providing the firm with Caliper's portfolio of imaging, microfluidics, automation, and sample preparation platforms and technologies. It also will combine Caliper's imaging instrumentation for in vivo imaging applications with PerkinElmer's broad offering of imaging reagents and set up the combined firm with further growth opportunities in molecular diagnostics.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.